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Abstract: We present a unique prospective study to estimate the median sustained stage-related improvement in pain and 
hand function in patients with trapezio-metacarpal joint osteoarthritis after administration of a single corticosteroid 
injection. Response to the corticosteroid injection was assessed using Disability of Arm Shoulder and Hand (DASH) and 
Visual Analogue Scale (VAS) pain scores. Self assessment scores revealed a reduction in pain and improvement in hand 
function. All patients reported a significant improvement in pain and hand function (p  0.05), regardless of the disease 
stage. Additionally, we observed a marked difference in the duration of improvement in hand function between early and 
late stages of the disease (p = 0.0046). In conclusion, it is possible to predict the period of symptomatic improvement at 
each of the four radiological stages of the disease. This would allow the treating clinician to judge the outcome of 
treatment with reasonable accuracy. 
INTRODUCTION 
  Carpometacarpal joint osteoarthritis at the base of thumb 
is a common problem in old age, particularly for women in 
the fifth to seventh decades. Estimated prevalence of the 
disease is 8% to 22% for women and 2% to 5% for men [1, 
2]. Severe symptoms are often precipitated by a fall or strain 
on the wrist, following which the joint may never settle. 
Non-operative treatment entails splinting, NSAIDs and intra-
articular injection of corticosteroids [3, 4], whereas surgical 
options include ligament reconstruction, excision 
arthroplasty and joint replacement [5-10]. Several guidelines 
recommend the use of intra-articular corticosteroids for the 
management of osteoarthritis. These drugs produce 
subjective improvement of symptoms in various anatomical 
regions [11-14] for a few weeks. But there is no consensus 
on their use, and no simple clinical predictors of response are 
available at present [15]. Thus, symptomatic relief following 
corticosteroid use depends on the biological history of 
individual patients. The use of intra-articular corticosteroids 
has been advocated in the basal thumb arthritis [5]. 
  The aim of this study was to estimate the improvement in 
pain and hand function in patients who had a single intra-
articular corticosteroid injection for thumb carpometacarpal 
joint (CMCJ) osteoarthritis. 
MATERIALS AND METHODS 
  We recruited forty consecutive patients displaying 
trapezio-metacarpal arthritis who fulfilled the inclusion 
criteria and consented to take part in the study, from the 
outpatients clinics. None of the patients had been treated 
previously with a steroid injection into the joint. Informed 
consent was obtained from all the participants. All patients 
received 10mg of Kenalog (0.5 ml) and a local anaesthetic 
solution into the joint. Patients were grouped into various  
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stages (I to IV), according to the radiological criteria [16], by 
three independent surgeons (Fig. 1 ). In case of dispute, a   
 
 
Fig. (1). The Dell’s radiological criteria for classification of 
trapeziometacarpal osteoarthritis. Stage I – Joint space narrowing 
and subchondral sclerosis but no evidence of subluxation or 
osteophyte formation. Stage II- Increased subchondral sclerosis and 
joint space narrowing. Formation of osteophyte at the ulnar border 
of the trapezium. Metacarpal is subluxated less than 1/3
rd of the 
diameter of the base of trapezium. Stage III- Further loss of joint 
space. More prominent osteophyte at the ulnar border of the 
trapezium. The metacarpal is subluxated more than 1/3
rd of base of 
the trapezium. Stage IV- Total loss of joint space, greater amount of 
subluxation/dislocation and the presence of pan-trapezial arthritis. Single Corticosteroid Injection in Thumb CMC Joint Osteoarthritis  The Open Orthopaedics Journal, 2009, Volume 3    49 
majority vote was counted. Inter-rater kappa values were 
calculated to determine consistency between individual 
surgeons’ X-Ray gradings. To establish whether patient 
groups based on the radiological stages were comparable, we 
compared gender, age and symptom duration of individuals 
between the four groups, using the Kruskal-Wallis test 
(Table  1). Patients were additionally assessed by a 
physiotherapist at six weeks after the injection. 
Table 1.  Details of the Four Patient Groups. Values Represent 
Median and Inter-Quartile Range 
 
Group  Gender  
(M/F) 
Age  
Mean and (IQR) 
Mean Duration of  
Symptoms (in Months) 
Stage I  1/5  63.4(53-72)  28 
Stage II  5/13  64.2 (58-78)  39 
Stage III  3/7  66.2 (57-80)  37 
Stage IV  2/4  66.6 (59-81)  41 
p value  0.8  0.4  0.09 
 
Outcome Measures 
1. Subjective Improvement in the Hand Function and Pain 
  Response was assessed with the aid of the Disability of 
Arm Shoulder and Hand (DASH) [17] score and a visual 
analogue score prior to the injection, and six weeks and three 
to six months post-injection. During every visit, patients 
were requested to fill in a DASH score and a visual analogue 
score. 
2. Duration of the Symptomatic Improvement 
  Patients were additionally asked to provide information 
on the duration of symptomatic improvement after the 
corticosteroid injection. The duration of symptomatic 
improvement was recorded on the basis of the patient’s 
memory. 
Statistical Analysis 
  At six weeks post-injection, improvement scores in hand 
function and pain were compared to pre-injection scores using 
the Wilcoxon signed-rank test for two related samples. 
Similarly, the DASH scores at six weeks were compared to 
three months and six months scores. Differences in 
improvement of hand function and pain at the early (I & II) and 
late (III & IV) stages of the disease were compared with the 
Mann-Whitney independent sample test. The DASH scores in 
Stage I and II patients were separately compared with those of 
Stage III and IV patients respectively, to overcome inaccuracies 
due to overlap between Stages II and III. 
  The Kaplan-Meier method was applied to estimate the 
median duration of sustained improvement at each stage of the 
disease, with 95% confidence intervals. The log-rank (Mantel-
Cox) test was performed to establish whether patient groups 
categorised on the basis of radiological grade differed in terms 
of the duration of symptomatic improvement. 
RESULTS 
  Forty patients were analysed, including 29 females and 
11 males. Patient ages ranged from 53 to 81 years, with a 
mean age of 65.1 years. No patients were lost to follow-up. 
The symptom duration period ranged from 3 months to over 
five years, with a mean duration of 36 months. Six patients 
were diagnosed with stage I disease, eighteen with stage II 
disease, ten with stage III disease, and six with stage IV 
disease. 
Radiological Grading of the Disease 
  There was moderate (weighted kappa: 0.58) to good 
(weighted kappa: 0.71) inter-rater agreement for the 
radiological grading of the disease. 
Subjective Outcome (DASH and VAS Scores) 
  Pre-injection visual analogue and DASH scores are 
presented in Table 2. At six weeks, twenty-six patients 
displayed a DASH score improvement of at least ten points. 
Four patients showed an improvement of lower than ten points, 
while DASH scores deteriorated in ten patients. At six weeks, 
reduction in the pain (visual analogue score) was evident in all 
but two patients. Pre-injection visual analogue scores were 
significantly higher (median = 7) than those recorded at six 
weeks (median = 3) (T = 0, p  0.05, r = -0.82). Similarly, the 
DASH score at six weeks (median = 43) was a significant 
improvement in all patients, in relation to the pre-injection 
DASH score (median = 57.5) (T = 0, p  0.05, r = -0.72). A 
significant deterioration was noticed in DASH scores in all 
patients, at three months (median 46) and six months (median 
52), as compared to six weeks stage (median 43) (p = <0.05) 
(Fig. 3). 
Table 2.  Baseline Function (DASH) and Pain (VAS) Scores at 
Different Stages of the Disease. Values Represent 
Medians and Inter-Quartile Ranges 
 
Stage of the  
Disease 
Pre-Injection  
DASH Scores 
Pre-Injection  
VAS Scores 
I  44 (32-64)  6 (5-7) 
II  52 (44-66)  6 (5-8) 
III  66 (40-75)  7 (6-8) 
IV  74 (54-91)  8 (7-9) 
 
  Stage-related improvement in pain (VAS) is presented in 
Table  4. At six weeks, the visual analogue score 
improvement in patients diagnosed with early stages (I & II) 
of the disease (median = 3) was not significantly different 
from patients in later stages (III & IV) of the disease (median 
= 2), (U = 130, p = 0.08, r = -0.26). At six weeks the 
improvement in DASH scores in early-stage patients 
(median = 14.5) was comparable to those in late-stage 
patients (median = 8.5), (U = 127, p = 0.07, r = -0.28). 
Moreover, at six weeks, the DASH score improvement in 
Stage I disease patients (median = 14.5) was comparable to 
that in Stage III disease patients (median = 4.5) (U = 130, p 
= 0.09, r = -0.25). Similarly, the DASH score improvement 
in Stage II disease patients (median = 14.5) was analogous to 
that in Stage IV disease patients (median = 8.4) (U = 143, p 
= 0.08, r = 0.27). 
  However, at three months and six months (Fig. 3) the 
DASH score in the early-stage patients (median = 8) was 50    The Open Orthopaedics Journal, 2009, Volume 3  Khan et al. 
significantly different from the late-stage patients (median = 
1.5), (U = 50, p = <0.05, r = -0.61). 
Duration of Symptomatic Improvement 
  Despite the comparable subjective improvement in hand 
function and pain between early and late stages of the 
disease at six weeks, there were significant differences (p = 
0.0046) in the duration of symptomatic improvement (Table 
3, Fig. 2). The duration of median sustained improvement in 
Stage I patients was 17 weeks. Most patients with stage II 
disease still reported improved hand function, at six months 
post-injection. In contrast, the reported median sustained 
improvement in Stage III and IV patients was only four 
weeks. 
 
Fig. (2). Kaplan-Meier curve showing the duration of symptomatic 
improvement at each stage of the disease. 
 
 
Fig. (3). DASH score in different radiological stages of the disease 
(Error bars show median & 95% Confidence intervals). 
DISCUSSION 
  This is a patient oriented study of the subjective 
improvement in pain and hand function following a single 
intra-articular injection of corticosteroid, for basal thumb   
 
Table 3.  Median Duration of Symptomatic Improvement at 
Each Stage of the Disease 
 
Stage of  
the Disease 
Median Duration of  
Symptomatic Improval (Weeks) 
95% CI 
I 17  (13,21) 
II  > 50% were still improved at 6 months.  - 
III 4  (2,6) 
IV 4  (2,6) 
 
Table 4.  Summary of the Changes in DASH AND Pain (VAS) 
Scores at Six Weeks, Compared to Pre-Injection 
Measures at Each Stage of the Disease. Values 
Represent Median and Inter-Quartile Range 
 
Stage of  
Disease 
Improvement in  
DASH Score 
Improvement in  
VAS Score  
I  14.5 (8-19)  4.0 (2-5) 
II  14.5 (12-16)  3.0 (3-7) 
III  4.5 (-6-15)  2.5 (2-4) 
IV  8.4 (2-19)  2.5 (0-6) 
 
arthritis. Our results showed that significant improvement in 
pain and hand function in patients with osteoarthritis of the 
thumb CMC joint can be achieved with a single 
corticosteroid injection. While the level of improvement 
achieved at six weeks was not related to the radiological 
stage, the duration of symptomatic improvement varied 
significantly, depending on the disease stage. This finding 
has two important implications. Firstly, corticosteroids 
improve pain and hand function, irrespective of the disease 
stage, and secondly, treatment with these drugs only 
provides long-term benefit at initial stages of the disease (I 
or II). At higher stages (III or IV), intra-articular 
corticosteroids may only be effective in patients awaiting 
definite surgical intervention. Furthermore, there was good 
inter-rater agreement for radiological staging of the disease 
using the Dell radiological criteria. Thus, we believe that our 
results can be easily reproduced in another clinical setting. 
  There are two limitations to our study. Firstly, we did not 
use fluoroscopy to ensure intra-articular delivery of 
corticosteroids. However, all injections were administered by 
an experienced physiotherapist. Moreover, the avoidance of 
fluoroscopy ensures that our results are more widely 
applicable, as fluoroscopy units are not generally available in 
outpatient departments. Secondly, relatively few patients 
with stage I disease were enrolled in the study, which may 
explain the unexpectedly short duration of symptomatic 
improvement, compared to stage II of the disease. 
  Day and colleagues [18] reported mean improvement for 
23 months with a single intra-articular corticosteroid 
injection in stage I disease. Only 35% of patients with stage 
II and III disease displayed sustained improvement. 
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Compared to their results, our stage I patients reported 
improvement for a shorter duration. However, it is important  
to note that patients in the earlier study wore splints, which 
made it difficult to estimate the improvement attributable to 
corticosteroid alone. Some patients in our study used splints, 
but were not requested to change their practice. We believe 
that this is a better way of estimating the effects of the intra-
articular corticosteroid, as the patient’s baseline status is left 
undisturbed. 
  In conclusion, stage I disease patients had sustained 
symptomatic improvement for 17 weeks, although the true 
duration is possibly between 13 and 21 weeks. Most stage II 
patients still report improvement at 6 months post-injection. 
Stage III and IV patients had an identical prognosis of 4 
weeks, although the true duration may be between 2 and 6 
weeks. The findings of this unique study should allow the 
treating clinician to confidently predict the outcome of an 
intra-articular corticosteroid injection in patients presenting 
with thumb CMC joint osteoarthritis. 
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